Clinical Trial

An Educational Intervention on Medication Adverse Effects in Patients With Resistant Hypertension (HTAR-CSI)

Study acronym: HTAR-CSI
Completed
View on ClinicalTrials.gov →
Summary
This randomized, single-blind controlled trial evaluates the effectiveness of a nurse-led educational intervention focused on the adverse effects of antihypertensive drugs-specifically sexual dysfunction and urinary incontinence-in patients with resistant hypertension. The intervention aims to improve treatment adherence and blood pressure control. The primary outcome is a reduction of ≥10 mmHg in systolic blood pressure, measured by ambulatory blood pressure monitoring (ABPM) before and after the intervention during routine and study-specific visits. The study targets adult patients on three or more antihypertensive medications who experience or are at risk of drug-related side effects. This educational approach is expected to enhance patient understanding, reduce treatment discontinuation, and improve clinical outcomes.
Trial Details
NCT Number NCT07589881
Lead Sponsor Consorci Sanitari Integral
Conditions Resistant Hypertension, Urinary Incontinence, Sexual Disfunction
Enrollment 46 participants
Start Date 2021-04-15
Primary Completion 2025-04-15 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-15